Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. - Wikidata - awgldk - TriplyDB

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

http://www.wikidata.org/entity/Q35187902

about

Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion Synthesis and evaluation of a ligand targeting the μ and δ opioid receptors for drug delivery to lung cancer.Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation.Synthesis and pharmacological evaluation of novel selective MOR agonist 6β-pyridinyl amidomorphines exhibiting long-lasting antinociception.

P2860

Q33815047-EE882908-C7EA-4253-9D77-2D5BD69C7005 Q36090988-CB99B003-DB19-41D8-B623-952D2E54CF14 Q36480105-06BA760E-BE63-41F7-848C-B0CAB43B61F5 Q37417284-D263DBE8-7D07-4905-995B-A86E10DEC546 Q38909015-F196C727-A324-4F83-9A9B-0C90DBD0AC80 Q44342749-3BE30C05-59DB-41F7-8A08-97B9EE003165 Q47147106-ABF74594-2A81-4E31-A356-A8BFEABA5D19

P2860

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

http://www.wikidata.org/entity/Q35187902

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

@ast

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

@en

type

label

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

@ast

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

@en

prefLabel

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

@ast

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

@en

P1433

Q35187902-79828835-7653-4595-A796-A997B9D428FF

P1476

Q35187902-048A592E-AB52-4745-A357-C856BF0F2404

P2093

Q35187902-4EA0007F-1A23-4527-A363-834425EF3F37

Q35187902-4FD36A9D-4C3F-48BB-816A-8997F274180D

Q35187902-A670D606-5EA4-464B-B7F4-717B90E75D7D

Q35187902-BA1F8CCD-71BB-4C45-AC86-391B3A425E1A

Q35187902-EE8C6BDD-009E-4E82-B37C-4337E09BB39A

P2860

Q35187902-195B16FA-C5C4-4584-8B45-9A3372DCB731

Q35187902-1A508C55-F50D-4DA0-8533-378333ADB954

Q35187902-2B94A476-0322-4343-BFA0-33897C46B103

Q35187902-2C39341C-FD95-41CC-B461-755D035369C6

Q35187902-346E6F2B-893B-4241-B615-5D19CB4F4713

Q35187902-3644C57A-7A21-4CF9-8713-64DB60E492DC

Q35187902-377C7A97-CFD2-4620-9877-DD81EFF16ECA

Q35187902-3E6BA33A-CFF4-4FFD-95E3-8B54FEAC6F93

Q35187902-41B7840D-9E34-455C-B110-7C0707C77BD6

Q35187902-4934B52B-07C0-40E8-9FAB-56BCE5CE1A69

P304

Q35187902-99B6E072-8FC4-4A6C-AA31-D50D6BB0F05F

P31

Q35187902-83F51566-C5D6-434E-9B69-8F67655D8A98

P356

Q35187902-EFE205AB-27C9-4268-A8E3-E0F7D8F0500B

P433

Q35187902-5605CA63-9E03-4CCB-A303-10197CF25879

P478

Q35187902-98777811-6426-4337-979A-26E624151D3C

P577

Q35187902-1008463C-D9E5-4F24-ABED-4025121767B7

P5875

Q35187902-1CAC64F3-DA0E-48E2-9363-0F3A0073CC70

P698

Q35187902-F48ED33E-F560-412C-874E-9282100B19C0

P932

Q35187902-0784A58A-600C-4B6A-83F1-F44FC8A082EF

P356

P1433

Drug Metabolism and Disposition

P1476

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.

@en

P2093

Jürgen Venitz

http://www.w3.org/2001/XMLSchema#string

Pallabi Mitra

http://www.w3.org/2001/XMLSchema#string

Phillip M Gerk

http://www.w3.org/2001/XMLSchema#string

Yan Zhang

http://www.w3.org/2001/XMLSchema#string

Yunyun Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport

Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity

Membrane transporters in drug development

Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.

Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.

Reward processing by the opioid system in the brain.

Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.

Opioid metabolites.

Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin.

P304

1589-1596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.111.038588

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51230716

http://www.w3.org/2001/XMLSchema#string

P698

21685245

http://www.w3.org/2001/XMLSchema#string

P932

3164275

http://www.w3.org/2001/XMLSchema#string